Aditi Shastri, MD
Internal Medicine · Houston, TXNPI 1568797058
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,300 of the $13,493 with a category attached, or 91.2%. 11 manufacturers reported payments, led by Geron Corporation at 46.4% of the total. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $518.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Geron Corporation$6K
- Gilead$4K
- Janssen Research & Development, LLC$3K
- Astellas Pharma US Inc$131
- Rigel Pharmaceuticals, Inc.$116
- AbbVie$109
- plus $149 from 5 others
Across 181 payments — averaging $1962.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$315K
- Bayer$40K
What the payments were for
- Consulting fees$12,30091%
- Travel & lodging$4373%
- Food & beverage$7566%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Geron Corporation | 11 | $6,260 |
| Gilead | 1 | $3,500 |
| Janssen Research & Development, LLC | 2 | $3,228 |
| Astellas Pharma US Inc | 2 | $131 |
| Rigel Pharmaceuticals, Inc. | 2 | $116 |
| AbbVie | 2 | $109 |
| Incyte Corporation | 1 | $40 |
| Sebela Pharmaceuticals Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Medtronic | 1 | $24 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMETELSTAT$6,037
- Rezlidhia$105
- Tavalisse$105
How this compares
$13,493 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InqoviDecitabine/Cedazuridine | 11 | $90,768 |
| SprycelDasatinib | 12 | $38,513 |
| Posaconazole | 12 | $16,031 |
| ValacyclovirValacyclovir Hcl | 40 | $949 |
| Prochlorperazine Maleate | 11 | $330 |
| Pantoprazole Sodium | 13 | $111 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.